Pasithea Therapeutics Corp's KTTA wholly-owned subsidiary, Pasithea Clinics, has administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression.
Pasithea Clinics commenced IV ketamine infusion therapy in Knightsbridge, London.
In sub-anesthetic doses, ketamine has shown efficacy and a rapid and sustained effect in some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.
Ketamine is an FDA-approved anesthetic and was introduced over 50 years ago. It has recently been repurposed in significantly lower doses to treat psychiatric disorders.
Pasithea has clinical partnerships to administer its IV ketamine treatment. In the U.K., Pasithea has partnered with ZEN Healthcare – a network of health clinics in London.
In the U.S., it has partnered with The IV Doc Inc to provide in-home IV ketamine infusions.
Related: EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK.
Price Action: KTTA shares closed 1.50% higher at $2.71 on Tuesday.
Photo: Michaelberry via Wikimedia
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!